Citi has initiated coverage of the "Big 6" European pharmaceutical companies, assigning Buy ratings to AstraZeneca, Novartis, and Roche. The Wall Street bank views the sector favorably, anticipating growth driven by innovation and a robust late-stage pipeline. The analysts expect average earnings-per-share growth of 7% in 2026.

This positive outlook comes as the sector navigates patent expirations and pricing pressures. Citi analysts believe new product launches will largely offset revenue losses. The combined late-stage pipelines of these companies hold potential risk-adjusted peak sales of $167 billion. 2026 is poised to be a catalyst-heavy year, particularly for AstraZeneca and Novartis.

Among the Buy-rated stocks, AstraZeneca is favored for its strong R&D pipeline. Novartis is expected to surpass sales growth expectations. Roche's rating is supported by its improving pipeline. Citi assigned Neutral ratings to GSK, Sanofi, and Novo Nordisk due to various headwinds.

For investors, this research provides a snapshot of where major financial institutions see value in the European pharma market. The sector's growth prospects and the potential for new product launches make it a key area to watch. The industry is constantly evolving, with several factors influencing stock performance.